Citadel Advisors
TLIS

Citadel Advisors’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Citadel Advisors’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,860
Closed -$13.4K – 15349
2023
Q2 		$13.4K Buy
+1,860
New +$13.5K ﹤0.01% 13044
2023
Q1 		– Sell
-7
Closed -$45 – 15723
2022
Q4 		$45 Buy
+7
New +$61 ﹤0.01% 14786
2022
Q1 		– Sell
-1,160
Closed -$70K – 14815
2021
Q4 		$70K Buy
+1,160
New +$86.8K ﹤0.01% 13032

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's TLIS Position: Q1 2024 in Review

Citadel Advisors sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q1 2024, closing a stake of 10,024 shares — an estimated $74.7K sold.

Citadel Advisors first reported a position in TLIS in Q3 2021 and held it in 6 quarters. The position peaked at $163K in Q3 2021. 18 funds tracked by Wall St. Rank hold TLIS as of Q1 2024.

  • Citadel Advisors reported no remaining Talis Biomedical Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 10,024 Talis Biomedical Corporation Common Stock shares in Q1 2024, an estimated $74.7K.
  • Citadel Advisors first reported a position in Talis Biomedical Corporation Common Stock in Q3 2021 and held it in 6 quarters.
  • Citadel Advisors's Talis Biomedical Corporation Common Stock position peaked at $163K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.